CardiaTec spun out of the University of Cambridge in 2021, co-founded by a world-leading computational drug discovery scientist, Professor Namshik Han, and ambitious alumni Raphael Peralta & Thelma Zablocki, motivated to change the drug discovery landscape for cardiovascular diseases and reduce its burden on public health.

Through the application of AI on multi-omics data we aim to deliver the next generation of drug targets with unparalleled biological interpretability.

CardiaTec is developing the OnTARGETS platform which unravels relationships across every layer of biology from gene variation, methylation and expression to their connection to proteomic and metabolomic functions. This gives comprehensive insights into the biological mechanisms underpinning disease development to uncover novel pathways and associated targets that once may have never been thought to be associated with cardiovascular diseases.